Company / R&D Expense
Edgewise Therapeutics, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$151.4M
FY2025
5-year range
$32.2M / $151.4M
FY2021-FY2025
Trend
+19.2%
vs FY2024
Sector context
#103 of 210
Health Care
What the data says
At $151M, Edgewise Therapeutics, Inc.'s r&d expense ranks #103 of 210 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $15M in FY2020 to $151M in FY2025.
Based on SEC 10-K filings.
$151M in FY2025 with a 5-year CAGR of +58.8%.
Improved from $91M to $151M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +41.0%
- 5-Year CAGR
- +58.8%
- 10-Year CAGR
- -
Sector benchmark
#103 of 210 in Health CareTop 49% of 210This company $151.4M Sector average $644.0M
▼
-76.5% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +58.8%, indicating consistent growth.
- In FY2025, r&d expense increased 19.2% year-over-year.
- Ranks #103 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $151.4M | +19.2% |
| FY2024 | $127.0M | +39.7% |
| FY2023 | $90.9M | +68.2% |
| FY2022 | $54.0M | +67.9% |
| FY2021 | $32.2M | +114.8% |
| FY2020 | $15.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026